文献速递心力衰竭与心肌病

全磁悬浮左心室辅助装置植入后两年结局:ELEVATE登记研究结果

Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry.
PubMed 文献 · Eur Heart J · 2020-01-01

ELEVATE登记研究在真实世界人群中评估全磁悬浮离心式左心室辅助装置Heartmate 3(HM3)的长期结局。共纳入540例患者,其中463例为首批植入HM3。首批植入队列2年生存率为83%,卒中发生率10.2%,消化道出血9.7%,泵血栓1.5%,流出道人工血管扭转3.5%。HM3植入带来功能能力和生活质量的显著且持续改善。

要点

  • 真实世界中HM3首批植入患者2年生存率达83%。
  • 泵血栓发生率低(1.5%),但卒中(10.2%)和消化道出血(9.7%)仍需关注。
  • HM3植入后功能能力和生活质量显著且持续改善。

核心结论

  • 在真实世界人群中,HM3左心室辅助装置植入展现出良好的长期生存、持续的功能能力改善以及低不良事件率(包括泵血栓)。

研究设计与样本

  • ELEVATE登记研究纳入欧洲和中东共540例患者,其中463例为首批植入HM3(首批植入队列),19例为泵更换(泵更换队列),58例为匿名队列(仅收集结局数据)。

主要发现

  • 首批植入队列2年生存率为83%。
  • 首批植入队列中卒中发生率为10.2%,消化道出血为9.7%,泵血栓为1.5%,流出道人工血管扭转为3.5%。
  • HM3植入带来功能能力和生活质量的显著且持续改善。

临床怎么用

  • HM3可作为真实世界终末期心力衰竭患者的长期左心室辅助支持选择,需关注卒中和消化道出血风险。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The ELEVATE Registry was designed to study long-term outcomes with the Heartmate 3 (HM3), a fully magnetically levitated centrifugal ventricular assist device, in a real-world population following CE-mark approval. METHODS AND RESULTS: A total of 540 patients, implanted in Europe and the Middle East were followed in ELEVATE. The registry included 463 patients receiving the HM3 as primary implant (Primary Implant Cohort), 19 patients underwent a pump upgrade from another device (Pump Exchange Cohort) and 58 patients who had experienced an outcome before having the possibility to sign the Informed Consent, for which only outcome data were collected (Anonymized Cohort). Data collection included demographics, survival, adverse events, EQ-5D Visual Analog Score quality of life (EQ-5D VAS QOL) questionnaire, and 6-min walk distance (6MWD). Mean age was 55.6 ± 11.7 years (89% male, 48% ischaemic cardiomyopathy). Seventy per cent of patients were in INTERMACS Profile 1-3 and 12.7% were on temporary mechanical circulatory support. Primary Implant Cohort survival was 83% after 2 years. In the Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation Primary Implant Cohort, strokes were observed in 10.2%, gastrointestinal bleedings in 9.7%, pump thrombosis in 1.5%, and outflow graft twists in 3.5%. Heartmate 3 implantation resulted in a significant and sustained improvement of functional capacity and QOL. CONCLUSION: In a real-world population, cohort implanted with the HM3 left ventricular assist device we demonstrate good long-term survival, sustained improvement of functional capacity, and low rates of adverse events (including pump thrombosis). CLINICALTRIALS.GOV IDENTIFIER: NCT02497950.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Zimpfer D, Gustafsson F, Potapov E, et al. Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry. Eur Heart J. 2020. PMID: 33107561. doi:10.1093/eurheartj/ehaa639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。